SCHEMBL20178669

SCHEMBL20178669

CCN1CCCc2ccc(C(=O)O)cc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 3/20 0.53
ALDH1A1 P00352 2/20 0.51
HRH3 Q9Y5N1 1/20 0.48
CHRM2 P08172 1/20 0.47
CHRM4 P08173 1/20 0.47
HDAC1 Q13547 7/20 0.46
HDAC6 Q9UBN7 7/20 0.46
GAA P10253 2/20 0.44
INMT O95050 1/20 0.44
ALPL P05186 1/20 0.43
ALPG P10696 1/20 0.43
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
CASP1 P29466 1/20 0.43
HTT P42858 1/20 0.43
CASP7 P55210 1/20 0.43
SMAD3 P84022 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5404613 0.92 ACHE (0.46) ACHEALDH1A1HRH3CHRM2GAA
SCHEMBL18593246 0.90 ACHE (0.49) ACHEHRH3CHRM2CHRM4HDAC1
SCHEMBL20178649 0.88 ALDH1A1 (0.52) ACHEALDH1A1HRH3CHRM2CHRM4
SCHEMBL3350583 0.86 ALDH1A1 (0.48) ACHEALDH1A1HRH3CHRM2CHRM4
SCHEMBL20178706 0.85 SRD5A1 (0.47) ACHEALDH1A1HRH3CHRM2CHRM4
SCHEMBL6856816 0.84 HRH3 (0.47) ACHEALDH1A1HRH3CHRM2CHRM4
SCHEMBL20178650 0.80 ACHE (0.54) ACHEALDH1A1GAAKDM4EMEN1
SCHEMBL4400467 0.80 CHRM2 (0.61) ACHEALDH1A1HRH3CHRM2CHRM4
SCHEMBL20119174 0.80 ALDH1A1 (0.56) ACHEALDH1A1GAAKDM4EMEN1
SCHEMBL1310717 0.79 HDAC1 (0.49) ACHEALDH1A1HRH3CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 ACHE 4086/4885ALDH1A1 2185/4885HRH3 582/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 ACHE 4086/4885ALDH1A1 2185/4885HRH3 582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.